Start page Newsroom All news Newsroom type All Releases Articles year All years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 reltype Press release Managers transactions Stock exchange release Flagging notifications Orion’s near-term climate targets approved by the Science Based Targets initiative 9/30/2024 Press release Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster 9/26/2024 Press release Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology 9/25/2024 Press release 213,285 Orion Corporation A shares converted into B shares 9/20/2024 Stock exchange release Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer 9/16/2024 Press release Inside information: Orion upgrades full-year outlook for 2024 9/11/2024 Stock exchange release Orion Corporation: Managers’ transactions – Satu Ahomäki 8/22/2024 Managers transactions Orion Corporation: Managers’ transactions – Niclas Lindstedt 8/21/2024 Managers transactions Orion Corporation: Managers’ transactions – Liisa Hurme 8/20/2024 Managers transactions Orion Corporation: Managers’ transactions – Hao Pan 8/15/2024 Managers transactions 44,767 Orion Corporation A shares converted into B shares 8/14/2024 Stock exchange release Orion Corporation: Managers’ transactions – Satu Ahomäki 8/12/2024 Managers transactions Orion Group Half-Year Financial Report January–June 2024 8/8/2024 Stock exchange release Orion Corporation’s financial reporting and Annual General Meeting in 2025 8/8/2024 Stock exchange release Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024 7/25/2024 Press release Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint 7/17/2024 Stock exchange release Inside information: Orion upgrades full-year outlook for 2024 7/1/2024 Stock exchange release Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer 7/1/2024 Stock exchange release